tetano
Editor, Senior Moderator
Med Drug Discov
. 2021 Jun;10:100085.
doi: 10.1016/j.medidd.2021.100085. Epub 2021 Mar 10.
The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review
Subham Das[SUP] 1 2 [/SUP], Anu Kunnath Ramachandran[SUP] 1 [/SUP], Sumit Raosaheb Birangal[SUP] 1 [/SUP], Saleem Akbar[SUP] 3 [/SUP], Bahar Ahmed[SUP] 3 [/SUP], Alex Joseph[SUP] 1 [/SUP]
Affiliations
Abstract
Recently, the pandemic outbreak of a novel coronavirus, officially termed as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), indicated by a pulmonary infection in humans, has become one of the most significant challenges for public health. In the current fight against coronavirus disease-2019, the medical and health authorities across the world focused on quick diagnosis and isolation of patients; meanwhile, researchers worldwide are exploring the possibility of developing vaccines and novel therapeutic options to combat this deadly disease. Recently, based on various small clinical observations, uncontrolled case studies and previously reported antiviral activity against SARS-CoV-1 chloroquine (CQ) and hydroxychloroquine (HCQ) have attracted exceptional consideration as possible therapeutic agents against SARS-CoV-2. However, there are reports on little to no effect of CQ or HCQ against SARS-CoV-2, and many reports have raised concerns about their cardiac toxicity. Here, in this review, we examine the chemistry, molecular mechanism, and pharmacology, including the current scenario and future prospects of CQ or HCQ in the treatment of SARS-CoV-2.
Keywords: COVID-19; Chloroquine; Coronavirus; Cytokine storm; Hydroxychloroquine; SARS-CoV-2.
. 2021 Jun;10:100085.
doi: 10.1016/j.medidd.2021.100085. Epub 2021 Mar 10.
The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review
Subham Das[SUP] 1 2 [/SUP], Anu Kunnath Ramachandran[SUP] 1 [/SUP], Sumit Raosaheb Birangal[SUP] 1 [/SUP], Saleem Akbar[SUP] 3 [/SUP], Bahar Ahmed[SUP] 3 [/SUP], Alex Joseph[SUP] 1 [/SUP]
Affiliations
- PMID: 33846702
- PMCID: PMC8026171
- DOI: 10.1016/j.medidd.2021.100085
Abstract
Recently, the pandemic outbreak of a novel coronavirus, officially termed as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), indicated by a pulmonary infection in humans, has become one of the most significant challenges for public health. In the current fight against coronavirus disease-2019, the medical and health authorities across the world focused on quick diagnosis and isolation of patients; meanwhile, researchers worldwide are exploring the possibility of developing vaccines and novel therapeutic options to combat this deadly disease. Recently, based on various small clinical observations, uncontrolled case studies and previously reported antiviral activity against SARS-CoV-1 chloroquine (CQ) and hydroxychloroquine (HCQ) have attracted exceptional consideration as possible therapeutic agents against SARS-CoV-2. However, there are reports on little to no effect of CQ or HCQ against SARS-CoV-2, and many reports have raised concerns about their cardiac toxicity. Here, in this review, we examine the chemistry, molecular mechanism, and pharmacology, including the current scenario and future prospects of CQ or HCQ in the treatment of SARS-CoV-2.
Keywords: COVID-19; Chloroquine; Coronavirus; Cytokine storm; Hydroxychloroquine; SARS-CoV-2.